Carrillo-Esper R, Sosa-García JO, Arch-Tirado E

Language: Spanish
References: 34
Page: 409-416
PDF size: 366.20 Kb.

ABSTRACT

Background: At the beginning of the second trimester of 2009 there was an influenza A (H1N1) outbreak. The aim of this study is to describe the clinical presentation and mortality of the severe form of pneumonia in patients with human influenza A H1N1.
Methods: We conducted a retrospective review of all files of confirmed and suspected patients with severe human influenza A (H1N1) pneumonia.
Results: We studied 26 patients admitted to the ICU from April 1 to December 31, 2009, among which 16 were males (61.54%) and 10 females (38.46%) with an average age of 52.26 ± 15.48 years. The time of onset of symptoms to admission to the ICU was 6.3 ± 3.19 days. The most frequent symptoms and signs were salmonated sputum (47%), chills (45%), dry cough (44%) and myalgia (42%). The mortality rate was 19.23%. The treatment was based on antiviral therapy, modulating inflammation and ventilatory techniques to optimize oxygenation. There was an association between combined therapy based on methylprednisolone, activated protein C and statins with a better survival (p = 0.05).
Conclusions: Pneumonia virus of human influenza A (H1N1) is associated with high morbidity and mortality. According to our results, it is recommended to make an early diagnosis and to initiate a treatment regimen based on treatment bundles designed to optimize oxygenation, reduce viral load and modulate inflammation.

REFERENCES

1. Ayora-Talavera G. Influenza: historia de una enfermedad. Rev Biomed 1999;10:57-61.

2. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine origin H1N1 influenza virus. Nature 2009;459:931-939.

3. Pérez PR, De la Rosa ZD, Ponce de León S, Hernández M, Quiñones FF, Bautista E, et al. Pneumonia and respiratory failure from swineorigin influenza A (H1N1) in Mexico 2009;361:1-10.

4. World Health Organization. Chan M. Influenza A (H1N1). El nivel de alerta de pandemia de gripe se eleva de la fase 5 a la fase 6. Disponible en http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/es/index.html

5. Secretaría de Salud de México. ¿Cómo se comporta la epidemia de influenza A (H1N1) en México? Disponible en http://portal.salud.gob.mx/contenidos/noticias/influenza/estadisticas.html

6. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 1999;73:5903-5911.

7. Dybing JK, Schultz-Cherry S, Swayne DE, Suárez DL, Perdue ML. Distinct pathogenesis of Hong Kong origin H5N1 viruses in mice compared to that of other highly pathogenic H5 avian influenza viruses. J Virol 2000;74:1443-1450.

8. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 2002;76:4420-4429.

9. Tran TH, Nguyen TL, Nguyen TD, Loung TS, Pham PM, Nguyen VC, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004;350:1179-1188.

10. Yuen KY, Chan PK, Peiris M, Tsang DN, Que TL, Shortridge KF, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998;351:467-471.

11. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006;12:1203-1207.

12. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002;360(9348):1831-1837.

13. World Health Organization. Interim WHO guidance for the surveillance of human infection with swine influenza A (H1N1) virus. Disponible en http://www.who.int/csr/disease/swineflu/WHO_case_definitions.pdf

14. Myers KP, Olsen CW, Gray GC. Cases of swine influenza in humans: a review of literature. Clin Infect Dis 2007;44:1084-1089.

15. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-1719.

16. Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, et al. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome. JAMA 2008;299:637-645.

17. Mercat A, Richard JC, Vielle B, Jaber S, Osman D, Diehl JL, et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome. JAMA 2008;299:646-655.

18. Domínguez CG, Lapinsky SE, Macías AE, Pinto R, Espinoza PL, de la Torre A, et al. Critically ill patients with 2009 influenza A (H1N1) in Mexico. JAMA 2009;302:1880-1887.

19. Gómez GA, Magaña AM, García SC, Ochoa PU, Falcón ER, Comas GA, et al. Severe pneumonia associated with pandemic (H1N1) 2009 outbreak, San Luis Potosi, Mexico. Emerg Infect Dis 2010;16:27-34.

20. Rello J, Rodríguez A, Ibáñez P, Socias L, Cebrián J, Marques A, et al. Intensive care adult patients with severe respiratory failure caused by influenza A (H1N1) in Spain. Critical Care 2009;13:R148.

21. Bin C, Xingwang L, Yuelong S, Nan J, Shijun C, Xiayuan X, et al. Clinical and epidemiologic characteristics of 3 early cases of influenza A pandemic (H1N1) 2009 virus infection, People’s Republic of China, 2009. Emerg Infect Dis 2009;15:1418-1422.

22. Winzer R, Kanig N, Schneitler S, Reuter S, Jensen B, Müller-Stöver I, et al. Early clinical experiences with the new influenza A (H1N1/09). Dtsch Arztebl Int 2009;106:770-776.

23. Rodríguez NE, González DE, Morfín OR, Gómez AG, Briseño RJ, Pérez GH, et al. Hospital triage system for adult patients using an influenza-like illness scoring system during the 2009 pandemic—Mexico. PLoS ONE 2010;5:e10658.

24. Hajjar LA, Schout D, Galas FR, Uip DE, Levin AS, Caiaffa Filho HH, et al. Guidelines on management of human infection with the novel virus influenza a (H1N1)a report from the Hospital das Clínicas of the University of São Paulo. Clinics 2009;64:1015-1024.

25. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374-1385.

26. Centers for Disease Control and Prevention. Intensive care patients with severe novel influenza A (H1N1) virus infectionMichigan, June 2009. MMWR Morb Mortal Wkly Rep 2009,58:749-752.

27. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, et al. Seasonal influenza in adults and childrendiagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Disease Society of America. Clin Infect Dis 2009;48:1003-1032.

28. WHO. Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and Other Influenza. Geneva: WHO; 2009.

29. Keller TT, van der Sluijs KF, de Kruif MD, Gerdes VE, Meijers JC, Florquin S, et al. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res 2006;99:1261-1269.

30. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003;31:834-840.

31. Fedson DS. Statin protection against influenza and COPD mortality. Chest 2007;132;1406-1407.

32. Almog Y. Statins, inflammation, and sepsis. Chest 2003;124;740-743.

33. Warnholtz A, Genth-Zotz S, Münzel T. Should treatment of sepsis includes statins? Circulation 2005;111:1735-1737.

34. Tang BM, Craig JC, Eslick GD, Seppelt I, McLean AS. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med 2009;37:1-10.